Translating Human Genetics into Better Drug Development Decisions
- Tuesday, October 20, 2026
- 13:00 – 15:00 EDT
- HoneyRose Hotel. 355 Blvd. De Maisonneuve Ouest, Montreal, Quebec H3A 1L6, Canada.
An invitation-only symposium on how human genetics and multi-omics evidence can improve target selection, clinical strategy, and portfolio decision-making.
Keynote Speaker
Robert Plenge, M.D., Ph.D.
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications Eli Lilly and Company
Confirmed Speaker
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications
Eli Lilly and Company
Sally John, Ph.D.
Senior Vice President, Information and Predictive Sciences Bristol Myers Squibb
Confirmed Speaker
Sally John, Ph.D.
Senior Vice President, Information and Predictive Sciences
Bristol Myers Squibb
Mark McCarthy, M.D.
Principal Fellow & Executive Director, Human Genetics, Research Biology Genentech
Confirmed Speaker
Mark McCarthy, M.D.
Principal Fellow & Executive Director, Human Genetics, Research Biology
Genentech
Brent Richards, MD, MSc
CEO and Founder
Host
Brent Richards, MD, MSc
CEO and Founder
5Prime Sciences
Human evidence is most valuable when it changes action
Human genetic and multi-omics evidence is increasingly central to drug discovery and development. Yet the field’s most important challenge is no longer simply generating more evidence — it is translating that evidence into decisions that can be used by teams across biology, chemistry, translational science, clinical development, business development, and portfolio strategy.
The most valuable evidence changes action: which targets to advance, which programs to stop, which patient populations to prioritize, which biomarkers to track, and where to invest before major capital is committed. This symposium will focus on the practical translation of human causal biology into drug development decisions.
Target selection
Direction of modulation
Biomarker strategy
Indication & patient population
Early clinical strategy
Portfolio & BD decisions
Confirmed Speakers
Host
Brent Richards, MD, MSc
Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Bristol Myers Squibb
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications Eli Lilly and Company
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications, Eli Lilly and Company
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications Eli Lilly and Company
Sally John, Ph.D.
Senior Vice President, Information and Predictive Sciences, Bristol Myers Squibb
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications Eli Lilly and Company
Mark McCarthy, M.D.
Principal Fellow & Executive Director, Human Genetics, Research Biology, Genentech
James L. Trevaskis, Ph.D.
Vice President, Obesity and Complications Eli Lilly and Company
Agenda
1:00 – 1:10 PM
CEO, 5 Prime Sciences
1:10 – 1:30 PM
VP, Obesity & Complications, Eli Lilly
1:30 – 2:15 PM
Making the case for human genetics and truly causal inference in drug development
Making high-stakes drug development decisions—Even in the absence of data
Robert M. Plenge, M.D., Ph.D., BMS
2:15 – 2:55 PM
2:55 – 3:00 PM
3:00 – 4:00 PM
When & where
Request your invitation
© 2026 5 Prime Sciences Inc. All rights reserved.